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Abstract
Background: It has become evident that intra-tumor heterogeneity of breast cancer impact on several biological
processes such as proliferation, migration, cell death and also might contribute to chemotherapy resistance. The
expression of Receptor Tyrosine Kinases (RTKs) has not been analyzed in the context of intra-tumor heterogeneity in
a primary breast cancer cell culture. Several subpopulations were isolated from the MBCDF (M serial-breast cancer
ductal F line) primary breast cancer cells and were successfully maintained in culture and divided in two groups
according to their morphology and RTKs expression pattern, and correlated with biological processes like
proliferation, migration, anchorage-independent cell growth, and resistance to cytotoxic chemotherapy drugs and
tyrosine kinase inhibitors (TKIs).
Methods: Subpopulations were isolated from MBCDF primary breast cancer cell culture by limiting dilution. RTKs
and hormone receptors were examined by Western blot. Proliferation was measure by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide (MTT assay). Cell viability was evaluated by Crystal Violet. Migration was assessed
using Boyden chambers. Anchorage-independent cell growth was evaluated by colony formation in soft agar.
Results: Several subpopulations were isolated from the MBCDF breast cancer cells that were divided into two
groups according to their morphology. Analysis of RTKs expression pattern showed that HER1, HER3, c-Met and
VEGFR2 were expressed exclusively in cells from group 1, but not in cells from group 2. PDGFR was expressed only
in cells from group 2, but not in cells from group 1. HER2, HER4, c-Kit, IGF1-R were expressed in all subpopulations.
Biological processes correlated with the RTKs expression pattern. Group 2 subpopulations present the highest rate
of cell proliferation, migration and anchorage-independent cell growth. Analysis of susceptibility to chemotherapy
drugs and TKIs showed that only Paclitaxel and Imatinib behaved differently between groups. Group 1-cells were
resistant to both Paclitaxel and Imatinib.
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Conclusions: We demonstrated that subpopulations from MBCDF primary cell culture could be divided into two
groups according to their morphology and a RTKs excluding-expression pattern. The differences observed in RTKs
expression correlate with the biological characteristics and chemoresistance of each group. These results suggest
that intra-tumor heterogeneity contributes to generate groups of subpopulations with a more aggressive
phenotype within the tumor.
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Background
Breast cancer is a heterogeneous disease that still is the
leading cause of cancer death among women worldwide
[1]. Depending on the molecular subtype the clinical out-
come is different [2]. Six molecular subtypes are com-
monly used to determined the course of treatment:
luminal A, luminal B, HER2 positive, basal-like, claudin-
low and normal-like breast that are determined by the
expression of estrogen, progesterone receptor and HER2
[3, 4]. Patients with luminal subtypes benefit from
endocrine-directed therapies, while HER2 positive subtype
has been associated with poor prognosis. However, HER2-
directed therapies have improved the response rates [5].
In recent years, it has become evident that besides the
inter-tumor heterogeneity, breast cancer tumors present
different subpopulations that can emerge from genetic
or epigenetic changes resulting in intra-tumor hetero-
geneity [6]. Techniques such as cytogenetic analysis,
chromosomal hybridization, microarray-based compara-
tive hybridization and massive parallel sequencing have
demonstrated that intra-tumor heterogeneity is a com-
mon phenomenon in breast cancer [7–11]. Frequent
mutations in genes such as TP53 and PI3KCA have been
shown by these techniques [12]. Despite all recent ad-
vances, intra-tumor heterogeneity is poorly understood,
and it still represents the main challenge to judge how
representative the analysis of a small biopsy is.
Advances in the understanding of tumor progression
have been essential for finding biomarkers that have
been useful to determine prognosis as well as targets
for drug development. Non-receptor and receptor tyro-
sine kinases have stood out as putative biomarkers, as
is the case of HER2 that has been described as a prog-
nostic and predictive marker for breast cancer. HER2
gene is amplified in 15–20 % of breast tumors with
concomitant HER2 overexpression [13]. Trastuzumab,
Pertuzumab and Lapatinib are HER2-directed therapies
that have been developed to treat breast cancer [5].
Other RTKs have been associated with poor prognosis
in invasive breast carcinomas. The EGFR/HER1 is
highly expressed in triple negative compared to other
subtypes and it has been associated with endocrine
therapy resistance [14, 15]. c-Met is another RTK that
is overexpressed in 20–30 % of breast cancer tumors
[16, 17]. Association between HER2 and c-Met contrib-
utes to resistance to HER2-directed therapy [18].
PDGFRs have also been associated with aggressive
breast cancer in advanced stages [19]. PDGFRs expres-
sion either in the tumor or the stroma correlates with
an aggressive phenotype and poor prognosis [20–22].
RTKs expression has not been analyzed in the context
of intra-tumor heterogeneity in breast cancer. In the
present work, we isolated subpopulations from a pri-
mary breast cancer cell culture; these subpopulations
were successfully maintained in culture. We analyzed
the RTKs expression pattern and then correlated it with
biological processes such as proliferation, migration,
and anchorage-independent cell growth as well as the
response towards cytotoxic chemotherapy and TKIs.
We observed that subpopulations could be divided into
two groups according to their morphology and their RTKs
pattern. The two groups have an excluding RTKs expres-
sion pattern where group 1 expresses HER1, HER3, c-Met
and VEGFR2, but it does not express PDGFR, and group 2
express PDGFR, but HER1, HER3, c-Met and VEGFR2
were not present. HER2, HER4, c-Kit, and IGF1-R are
present in all subpopulations in variable amounts. PDGFR
positive subpopulations have the highest rate of cell prolif-
eration, migration and anchorage-independent cell growth,
and they are highly sensitive to Imatinib and Paclitaxel.
Other chemotherapy drugs such as Doxorubicin and
Capecitabine, as well as Lapatinib and Crizotinib have
similar effects on cell viability in all subpopulation tested.
These results suggest that the RTKs are expressed in an
excluding manner in subpopulations of a heterogeneous
breast cancer primary cell culture where the presence of
PDGFR confers a more aggressive phenotype. Altogether,
these data ratify that breast cancer intra-tumor heterogen-
eity may contribute to invasion, metastasis and therapy




MBCDF primary breast cancer cell culture was previ-
ously described [23]. Briefly, a biopsy was obtained
from a radical mastectomy from a patient with breast
cancer (Protocol approved by the Ethics and Research
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Committee of the Instituto Nacional de Ciencias
Médicas y Nutrición “Salvador Zubirán” (INCMNSZ),
Ref. 1549, BQO-008-06/9-1). Written informed consent
was obtained from the patient. Tissue was minced and
grown as explants in RPMI-1640 plus 10 % fetal bovine
serum (FBS). After cells filled the plate, they were trypsi-
nized and grown as a regular cell line. T47D, SK-BR-3 and
MCF-7 are from ATCC (Donated by Dr. Rocío Becerra,
INCMNSZ). Dr. Alejandro Zentella (INCMNSZ) donated
HUVECs.
Subpopulations isolation by limiting dilution method
MBCDF cells were diluted to 1 cell/200 μl of RPMI-
1640 plus 10 % FBS. One hundred microliters were
seeded in 96-well plates and grown at 37 °C and 5 %
CO2. Single colonies were sequentially expanded to 12-
well plates, 6-well plates and 100 mm plates. Then sub-
populations were grown as regular cell cultures.
Antibodies
The antibodies against HER2, c-Met and VEGFR
were purchased from Cell Signaling Technology
(Danvers, MA, USA). The antibodies against estro-
gen and progesterone receptors were obtained from
Cell Marque (Rocklin, CA, USA). The following anti-
bodies were acquired from Santa Cruz Biotechnology
(Santa Cruz, CA, USA): HER1, HER3, HER4, IGFI-R,
PDGFR.
Western blotting
Breast cancer cells were lysed in a buffer containing
50 mM HEPES (pH 7.4), 1 mM EDTA, 250 mM NaCl,
1 % Nonidet P-40, 10 mM NaF, 1 mM sodium vanadate
and 1× protease inhibitor cocktail (Complete EDTA-free,
Roche Diagnostics, Mannheim, Germany). Twenty mi-
crograms of whole protein extract was run in a SDS-
PAGE and transferred to Immobilon-P PVDF mem-
brane (Millipore, Bedford, MA, USA). Membranes were
blocked with 5 % non-fat milk in PBS-Tween. Mem-
branes were probed with the respective primary anti-
bodies at 4 °C overnight. Secondary HRP-conjugated
anti-mouse or anti-rabbit antibodies (Jackson Immu-
noResearch, West Grove, PA, USA) were used according
to the respective primary antibody. Immunodetection was
performed using Supersignal West Pico Chemilumines-
cent Substrate (Thermo Scientific, Rockford, IL, USA).
Cell proliferation assay
Breast cancer cells were seeded at a density of 15 000
cells/cm2 in 24-well plates in RPMI-1640 supplemented
with 10 % FBS. Cell proliferation was quantified by
MTT reduction (3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyl-tetrazolium bromide, Sigma-Aldrich, St Louis, MO,
USA). Formazan salt was dissolved in acid isopropanol
and absorbance was read at 570 and 630 nm in an
ELISA plate reader. Results are expressed as the increase
in absorbance (570–630 nm) of cells at different days
over the absorbance at day 0. Experiments were per-
formed at least three times in triplicate.
Cell migration assay
Migration assay was performed in a 24-well transwell
chamber with 8 μm pore size membranes. MBCDF’s
subpopulations were seeded at 30 000 cells in 200 μl of
RPMI-1640 plus 10 % FBS in the upper chamber and in-
cubated for 6 h at 37 °C and 5 % of CO2. After this time
the non-migrating cells in the upper chamber were re-
moved with a cotton swap. Then migrating cells were
fixed with 1.1 % of glutaraldehyde in PBS for 20 min and
stained with Crystal Violet. Dye excess was removed
with water. Number of cells was counted from five fields
under the microscope at 20×. Its average was multi-
plied by viewing field area (0.001 cm2) and then
multiplied by the Transwell insert area (0.33 cm2),
giving the total number of migrated cells. To obtain
the percentage of migration, the number of migrated
cells was divided by the number of seeded cells and
then multiplied by 100.
Soft agar assay
To evaluate anchorage-independent cell growth, an assay
of colony formation in soft agar was performed. A bot-
tom layer was formed with 0.5 % agar and RPMI-1640
plus 10 % FBS in 6-well plates. After the bottom layer
solidified, the top layer containing 2500 cell/plate,
0.35 % agar and RPMI-1640 plus 10 % FBS was added.
Plates were fed every other day for 15 days at 37 °C and
5 % CO2. Colonies were stained with 0.005 % Crystal
Violet. Experiments were performed at least three inde-
pendent times in triplicate.
Cytotoxicity assay
Breast cancer cells were seeded at 10 000 cells/cm2 in
48-well plates. Increasing doses of the indicated chemo-
therapy agents were added and incubated for 48 h at
37 °C and 5 % CO2. After this time, cells were fixed for
20 min with 1.1 % glutaraldehyde in PBS, and then
stained with Crystal Violet. Dye was dissolved with 10 %
acetic acid, and the absorbance was read at 570 nm in
an ELISA plate reader. Results are expressed as percentage
absorbance at a given concentration over the absorbance
of non-treated or vehicle. Experiments were performed
three independent times in triplicate.
Gene silencing by shRNA
MBCDF and its subclone F3 cells were transfected by li-
pofectamine with four different plasmids pGFP-V-RS
containing the following shRNAs sequences specific
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5’ TGCCTCCGACGAGATCTATGAGATCATGC 3’ or
irrelevant scramble sequence as negative control. Forty-
eight hours after transfection cells were split and plated
in presence of 5 μg/ml of Puromycin.
Statistical analysis
Statistical analysis was performed by GraphPad Prism
v_6.0e for MacOs X (GraphPad Software, La Jolla,
CA, USA). Significant difference was determined by
one-way ANOVA. In TKIs combination assays, we
performed Student’s t test to evaluate differences be-
tween groups. Data were considered statistically sig-
nificant if P < 0.05.
Results
Isolation of MBCDF primary breast cancer cells
subpopulations
Previously described MBCDF primary breast cancer
cells were cultured by growing explants from a mast-
ectomy biopsy (Fig. 1) [23]. To study breast cancer
intra-tumor heterogeneity, subpopulations were isolated
from MBCDF primary breast cancer-derived cells by limit-
ing dilution. Twenty different subpopulations were
obtained and were classified into two groups according to
their morphology. Group 1 has 8 different subpopulations
that are characterized by multipolar shape and large cyto-
plasm (B3, B4, B5, B6, C1, C3, C4 and D5). Group 2
includes 12 subpopulations (B2, B7, B10, C5, C9, D4, F3,
F5, F7, F8, F10, G11) with polygonal shape and small cyto-
plasm (Fig. 1).
RTKs expression in MBCDF’s subpopulations
The twenty MBCDF’s subpopulations were characterized
by the expression of different RTKs. Using Western blot
analysis, we explored the expression of HER1, HER2,
HER3, HER4, PDGFR, c-Kit, c-Met, IGF1R, VEGFR2, and
hormonal receptors (estrogen and progesterone recep-
tors); SKBR3, MCF-7 cell lines as well as MBCDF were
used as control to compare the difference among the par-
ental cells and the subpopulations (Fig. 2). We found an
exclusive expression of HER1, HER3, and c-Met in group
1 subpopulations (Fig. 2a, left panel), as well as VEGFR2.
The expression of VEGFR2 in the MBCDF’s subpopula-
tions was compared with HUVECs (Fig. 2b, left panel). In
the same manner, PDGFR is exclusively expressed in sub-
populations from group 2 (Fig. 2a, right panel). HER2,
HER4, c-Kit, IGF1-R are indistinctly expressed in all sub-
populations. Interestingly, B2 cells were the only subpopu-
lation where HER1, HER3 and PGDFR were expressed
together. We did not detect expression of ER or PR in any
subpopulation; this is in agreement with the MBCDF
negative status for hormonal receptors (Fig. 2c). These re-































































Fig. 1 Establishment of a MBCDF primary breast cancer cell culture and subpopulations. Breast tumor biopsy was obtained from a radical
mastectomy. Tissue was minced and plated as explants. Cells were grown until they filled the plate. Twenty subpopulations were isolated by
limiting dilution and classified into two groups according to their morphology
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primary breast cancer cell culture, where different sub-
populations can be found with a heterogeneous RTKs
repertoire with an excluding expression among some of
them. Table 1 shows the qualitative amount comparison
of the RTKs among the subpopulations.
Cell proliferation, cell migration and anchorage-
independent cell growth of MBCDF’s subpopulations
To investigate potential biological consequences of the
different RTKs expression on the MBCDF’s subpopula-
tion, we evaluated the rates of cell proliferation and cell
migration. First, we performed cell proliferation assays on
selected subpopulations from each group. We found that
F3 cells that belong to group 2 matched the parental
MBCDF cells at day 6 at 20 fold. B2 and C9, also from
group 2, had an intermediate rate of cell proliferation at
10 fold. B3 and D5 cells from group 1 were slightly
below of B2 and C9. Group 1, C1 and B6 subpopula-
tions, had the lowest rate of cell proliferation
(Fig. 3a). Our results showed that group 2 subpopu-
lations had a higher capacity to proliferate compared
to group 1.
During tumor progression, cells acquire the ability
to transmigrate and grow in an anchorage-
independent manner. For this reason, we evaluated
cell migration by Boyden chamber assay and
anchorage-independent cell growth by soft agar assay.
In the migration assays, we found that subpopulations
from group 2, B2 and C9, migrated the most and
there were no significant differences with the MBCDF
parental cells. F3 cells, despite being from group 2






























































































































































































Fig. 2 Tyrosine kinase receptors and hormonal receptors expression in MBCDF’s subpopulations. Expression of all receptors was analyzed by
Western blot. B2 and D5 were included in their opposite group as controls. Breast cancer cell line SKBR3 was used as control of HER2 expression,
and MCF-7 cells were included as a positive control for the expression of ER and PR. a HER1, HER2, HER3, HER4, PDGFR, c-Kit, c-Met, IGF1-R expression.
Actin was used as loading control. b VEGFR2 expression. Protein extracts from HUVECs were used as positive control and Tubulin as loading control. c
ER and PR receptors expression. Actin was used as loading control
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from group 1 (Fig. 3b). Fig. 3c shows representative
pictures of Boyden chamber assays.
In the anchorage-independent colony formation
assay, subpopulations from group 2 were capable to
grow in soft agar compared with the subpopulations
from group 1 that they did not form colonies. B2 and
F3 had slightly more number of colonies than
MBCDF parental cells. C9 subpopulation formed less
and smaller colonies. Interestingly, T47D breast can-
cer cell line known for its ability to form colonies in
soft agar did not show as many colonies as MBCDF
cells (Fig. 4a). The number of colonies were counted
and graphed: about 292 colonies were generated in
B2 cells; F3 and MBCDF had approximately 245 col-
onies, and C9 had around one hundred colonies.
T47D formed an average of 14 colonies (Fig. 4b). To-
gether these data show that the different RTK’s
expression pattern influence biological processes such
as cells proliferation, migration and anchorage-
independent cell growth. In particular, PDGFR expres-
sion seems to drive positively these processes.
Effect of chemotherapy agents on the cell viability of
MBCDF’s subpopulations
Having determined the influence of the RTKs expression
pattern on cell proliferation, migration and anchorage-
independent cell growth in the MBCDF’s subpopula-
tions, we studied the response of these subpopulations
to the chemotherapy agents: Doxorubicin, Capecitabine
and Paclitaxel. These drugs are considered cytotoxic:
Doxorubicin is an anthracycline that intercalates into
the DNA, Capecitabine is an alkylating agent and Pacli-
taxel is a taxane that stabilize microtubules. We per-
formed cell viability assays with increasing doses of
Doxorubicin, Capecitabine and Paclitaxel (Fig. 5). We
found that Doxorubicin and Capecitabine treatment in-
duced a decrease on cell viability in a dose-dependent
manner; however, these drugs did not show any signifi-
cant difference among the MBCDF’s subpopulations
(Fig. 5a, b). In the case of Paclitaxel treatment, subpopu-
lations from group 1 (B3, D5, C1, B6) were more resist-
ant to its cytotoxic effect. At 0.5 μg/mL of Paclitaxel the
cell viability dropped 60 %, remained steady at 1 μg/mL
and declined between 5 and 10 % at 5 and 10 μg/mL.
Subpopulations from group 2 were more sensitive to
Paclitaxel; at 0.5 μg/mL cell viability declined 40 %,
continued steady at 1 μg/mL and fell down below 5 % at
5 and 10 μg/mL (Fig. 5c). These data demonstrate that
Paclitaxel is the only cytotoxic drug that showed a differ-
ence between the two groups of subpopulations.
Tyrosine kinase inhibitors effect on the cell viability of
MBCDF’s subpopulations
Since we observed a RTKs excluding pattern between
group 1 and group 2, we analyzed whether the RTKs
distribution influence the susceptibility to tyrosine
kinase inhibitors. We did viability assays as in Fig. 5,
but in this case using Lapatinib, a HER1 and HER2
inhibitor; Crizotinib that targets c-Met and Alk; and
Imatinib, an inhibitor of PDGFR, Abl and c-Kit.
Treatment with either Lapatinib or Crizotinib did not
show significant differences between the two groups
of subpopulations (Fig. 6a, b). MBCDF subpopulations
showed significant difference to Imatinib treatment.
Subpopulations from group 1 presented marked re-
sistance to Imatinib from 0.01 to 0.5 μM, then cell
viability declined in dose dependent manner from 1
to 10 μM. In the case of subpopulations from group
2 treated with Imatinib, cell viability declined in dose
dependent manner from 0.01 to 0.05 μM, remaining
steady up to 0.5 μM, and cell viability dropped below
15 % (Fig. 6c). These data demonstrate that some
RTKs influence the response to TKIs; in particular,
PDGFR expression sensitizes breast cancer cells to
Imatinib. In order to confirm this hypothesis, we si-
lenced the expression of PDGFR gene in MBCDF and
Table 1 Expression of RTKs in MBCDF’s subpopulations
Subclone HER1 HER2 HER3 HER4 PDGFR c-Met IGF-1R VEGFR2
Group 1
B5 +++ +++ ++ − − + + −
B6 +++ + +++ − − +++ +++ +
C1 +++ + ++ − − ++ + ++
C3 +++ ++ ++ − − +++ + ++
C4 +++ + +++ − − ++ ++ ++
D5 +++ + ++ − − + +++ +
B3 ++ ++ + + − +++ +++ ++
B4 + + + − − + +++ ++
Group2
B2 ++ +++ + − ++ − +++ −
B7 − + + − +++ − ++ −
B10 − + + − +++ − ++ −
C5 − ++ + − ++ − + −
C9 − +++ + − +++ − ++ −
D4 − +++ + − ++ − + −
F3 − + + − +++ − +++ −
F5 − ++ + − ++ − + −
F7 − + + − + − + −
F8 − +++ + − ++ − ++ −
F10 − +++ + − ++ − − −


























Fig. 3 (See legend on next page.)
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F3 with specific shRNA. PDGFR expression was
significantly reduced after transfection with specific
PDGFR shRNAs, but not after transfection with a
control scramble shRNAs. As expected treatment with
increasing doses of Imatinib induced a significant
decrease on viability of both MBCDF sh control and
F3 sh control cells transfected with the irrelevant
shRNA. However, silencing of PDGFR resulted in par-
tial resistance to Imatinib (Additional file 1: Fig. S1).
Effect of combinations of tyrosine kinase inhibitors on
MBCDF’s subpopulations viability
In order to explore a putative translational implication
of inhibition of RTKs in MBCDF’s subpopulations, we
treated the cells with a combination of Crizotinib with
Imatinib and Lapatinib with Imatinib. First, we treated
subpopulations from group 1 and group 2 with increas-
ing doses of Crizotinib (0, 0.1, 0.5 and 1 μM) and a
fixed dose of Imatinib (1 μM). We found that treat-
ment with Crizotinib-Imatinib had no further cytotoxic
effect than Crizotinib alone in cells from group 1.
However, Crizotinib-Imatinib combination induced an
increment in cell death on group 2 cells with a general
additive effect (Fig. 7a). Next, we evaluated a combin-
ation of Lapatinib-Imatinib in MBCDF’s subpopula-
tions. We used increasing doses of Lapatinib (0, 0.05,
0.1 and 0.5 μM) and a fixed dose of Imatinib (1 μM).
We found similar results to those obtained with the
combination of Crizotinib-Imatinib, where in group 1
cells the effect of Lapatinib was not improved by the
addition of Imatinib. Nevertheless, Lapatinib-Imatinib
combination increased the cell death of group 2 cells
(Fig. 7b). These data suggest that a putative transla-
tional used of these TKIs depend on the expression
pattern of RTKs.
Discussion
In this work, we isolated and maintained several subpopu-
lations from a primary breast cancer cell culture
(MBCDF) [23]. The subpopulations were divided into two
groups according to their morphology. The analysis of
RTKs expression was correlated with biological processes
such as cell proliferation, migration and anchorage-inde-
pendent cell growth. We also linked each group with
the susceptibility to cytotoxic chemotherapy drugs and
TKIs. The data presented in this study ratifies breast
cancer tumor heterogeneity as has been shown before
[24–26], and this is the first time that subpopulations
from a primary breast cancer cells are successfully
maintained in cell culture with a stable phenotype.
(See figure on previous page.)
Fig. 3 Cell proliferation and migration of MBCDF’s subpopulations. a For cell proliferation, B3, B6, C1, D5 (Group 1), B2, F3, C9 (Group 2) subpopulations
were seeded at 15 000 cells/cm2 in 24-well plate in RPMI plus 10 % FBS. Cell proliferation was evaluated by MTT at the days 0, 2, 4, and 6. Results are
presented as the mean ± SEM of three independent experiments seeded in triplicate. ** P< 0.05. b Migration assays were performed using Boyden
chambers. Thirty thousands cells of B3, B6, C1, D5 (Group 1), B2, C9, F3 (Group 2) subpopulations were seeded in the upper chamber in RPMI plus 10 %
FBS and incubated for 6 h at 37 °C. After this time the cells that did not migrate were removed from the upper chamber. Cells that migrated were fixed
and stained with Cristal Violet. Five fields were counted under the microscope at 20×. c Representative pictures of Boyden chamber assays. The percentage



















Fig. 4 Colony formation of MBCDF’s subpopulations on soft agar.
Anchorage-independent cell growth of B3, B6, C1, D5 (Group 1), B2,
C9, and F3 (Group 2) subpopulations was evaluated by soft agar
assay. A bottom layer of 0.5 % of agar in RPMI plus 10 % FBS was
placed. The top layer contained 0.35 % agar in RPMI plus 10 % FBS
and 2500 cell/plate. Colonies were analyzed after 15 days of culture.
MBCDF and T47D were used as positive controls of colony formation.
Agar without cells was used as negative control. a Representative
picture of colony formation of each subpopulations are presented. b
Cells were photographed and counted. The graph represents the
mean ± SEM. Soft agar assay was performed three independent
times in triplicate
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The concept of tumor heterogeneity is well estab-
lished in cancer research [24–27], and several studies
have addressed breast cancer tumor heterogeneity.
These works most of the times have been searching for
gene amplification [26, 28–30]. Few studies have ana-
lyzed the relation among some RTKs such as members
of the HER family with c-Met [18]. We analyzed a
broader number of RTKs that showed an excluding
expression pattern. Overall, we found that group 1 ex-
presses solely HER1, HER3, c-Met and VEGFR2, but
not PDGFR that is limited to group 2. Other RTKs
(HER2, HER4, c-Kit and IGF-1R) have variable expres-
sion with no significant pattern among subpopulations.
It is well established that RTKs regulate biological
processes and are submitted to major regulatory mech-
anisms. Here, we found a correlation between the
RTKs expression and biological processes such as pro-
liferation, migration and anchorage-independent cell
growth. Subpopulations from group 1 have poor cell
proliferation, migration and anchorage-independent
cell growth. Interestingly, expression of PDGFR in sub-
populations from group 2 correlates with high cell pro-
liferation, migration and anchorage-independent cell
growth; these results suggest that PDGFR might play
an important role in these biological processes. Our re-
sults agree with a recent report showing that inhibition
of PDGFR with TKIs inhibits cell proliferation and mi-
gration of breast cancer cell lines [31]. Furthermore,
the expression of PDGFR in the stroma and cancer
cells has been associated with poor prognosis of breast
cancer patients [20–22].
Despite the advances in breast cancer treatment, the
mortality of this disease is still high due to the develop-
ment of resistance to either cytotoxic therapy or tar-
geted therapy. Heterogeneous tumors may contain
subclones with either intrinsic or acquired resistance.
Furthermore, subpopulations under selective pressure
by treatment can give rise to new cancer cells with the
potential to drive progression of the disease [32]. We
analyzed the effect of several cytotoxic and targeted
therapy agents on the MBCDF subclones. Three cyto-
toxic drugs (Doxorubicin, Capecitabine and Paclitaxel)
and three targeted therapies (Lapatinib, Crizotinib and
Imatinib) were tested. Paclitaxel and Imatinib were the
only drugs that presented significant differences be-
tween the two groups. Group 1 was resistant to Pacli-
taxel and Imatinib; an opposite effect was observed in
subclones from group 2, sensitive to Paclitaxel and
Imatinib. Cell reprogramming through an epithelial-
mesenchymal transition (EMT) program might be a pu-
tative mechanism of Paclitaxel resistance, since there is
evidence that this process contributes to metastasis as
well as drug resistance [33, 34]. Further studies remain
to be performed to determine the Paclitaxel resistance
mechanism in cells from group 1.
Imatinib resistance in group 1 subclones could be
explained by the lack of PDGFR. We proved that silen-
cing of PDGFR by shRNAs induced partial resistance to
Imatinib. We have previously demonstrated that the sen-
sitivity to Imatinib relies also in part on c-Abl kinase in
breast cancer cell lines as well as primary cell culture
MBCDF [23]. A putative translational implication of the
diverse RTKs expression pattern described here would
be co-targeting the different types of subpopulations in a
tumor. We explored the combination of TKIs that target
RTKs from each group. Interestingly, the combination of
Crizotinib with Imatinib or Lapatinib-Imatinib had an
additive effect only on group 2 subpopulations, but no
in the cells from group 1, where it was only observed
the effect of Crizotinib or Lapatinib alone. The presence
of PDGFR in group 2 cells seems to be important to in-
crease cell death with these combinations. Also, these
combinations might be potentially useful in the treat-
ment of breast cancer patients that have combined ex-
pression of RTKs such as PDGFR, c-Met and HER
family members. It is clear that group 1 cells are resist-
ant to TKIs either alone or in combination, for this rea-
son it is necessary to find a better combination either of
TKIs or TKIs with classical chemotherapy to improve
cell death on group 1 cells.
MBCDF primary cell culture is classified as HER2+;
most of its subpopulations present different amounts of
HER2, except the subclone B4 that can be catalogued
as a triple negative. Another interesting subclone is B2
that co-expressed PDGFR with HER1, HER3, c-Met and
VEGFR2; despite expressing group 1 receptors, B2 cells
behave mainly as group 2 subpopulation with high prolif-
eration, migration, anchorage-independent cell growth, as
well as sensitivity to Paclitaxel and Imatinib. The data from
B2 cells support a major role of PDGFR in the biological
processes studied. Moreover, HER2, HER4, c-Kit and IGF-
1R are expressed in different amounts without any specific
correlation; however, these RTKs might participate in the
resistance to chemotherapy. For example, expression of
(See figure on previous page.)
Fig. 5 Effect of Doxorubicin, Capecitabine and Paclitaxel on cell viability of MBCDF’s subpopulations. B2, C9, and F3 (Group 2), B3, B6, C1, D5
(Group 1) were seeded at 10 000 cells/cm2. a Doxorubicin was used at 0, 0.005, 0.01, 0.05, 0.1, 0.5, 1 and 5 μg/mL. b Capecitabine was added at 0,
25, 50, 100, 200, 400, 600 and 800 μg/mL. c Paclitaxel was added at 0, 0.5, 1, 5 and 10 μg/mL. Viability was evaluated 48 h after addition of the
drugs by Crystal Violet assay. Data represent the mean ± SEM of three independent experiments seeded in triplicate. **P < 0.001
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Fig. 6 (See legend on next page.)
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IGF1-R has been associated with resistance to Trastuzu-
mab [35, 36]. Further studies need to be done to determine
putative crosstalk among these RTKs.
Conclusions
These report demonstrate intra-tumor heterogeneity in
the MBCDF primary breast cancer cell culture. MBCDF is
composed of several subpopulations with different RTKs
profile. Some of the RTKs showed an excluding pattern
among the subpopulations. Breast cancer subpopulations
with a particular expression of RTKs correlate with bio-
logical processes such as proliferation, migration and
anchorage-independent cell growth and response to
chemotherapy agents. The intra-tumor heterogeneity ob-
served in the MBCDF primary breast cancer cell culture
suggests that subpopulations with a specific RTKs reper-
toire may have a more aggressive phenotype within the
tumor. These results open the door to address new
schemes of treatment for breast cancer patients focusing
in the RTK pattern of tumor subpopulations.
(See figure on previous page.)
Fig. 6 Effect of Lapatinib, Crizotinib and Imatinib on cell viability of MBCDF’s subpopulations. B2, F3, C9 (Group 2), B3, D5, C1, B6 (Group 1) were
seeded as in Fig. 5. a Lapatinib was used at the following concentrations: 0, 0.001, 0.01, 0.1, 0.5 and 1 μM. b Crizotinib was added at 0, 0.01, 0.05,
0.1, 0.5, 1, 5 and 10 μM. c The following concentrations were used for Imatinib: 0, 0.01, 0.05, 0.1, 0.5, 1, 5 and 10 μM. Cell viability was evaluated as























































































































































































































































































































































Fig. 7 Effect of the combinations Crizotinib-Imatinib, and Lapatinib-Imatinib on cell viability. MBCDF and its subpopulations: D5, B6, B3, C1 (Group
1, left panel), F3, C9, B2 (Group 2, right panel) were seeded as in Fig. 5. a Crizotinib was used at the following concentrations: 0, 0.1, 0.5 and 1 μM
with Imatinib 1 μM. b Lapatinib was added at 0, 0.05, 0.1, 0.5 μM plus Imatinib 1 μM. Cell viability was evaluated as in Fig. 5. Data represent the
mean ± SEM of three independent experiments seeded in triplicate. * P < 0.05 versus Crizotinib or Lapatinib alone
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Additional file
Additional file 1: Fig. S1. Effect of PDGFR silencing on Imatinib-induced
cytotoxicity. MBCDF (a) and subclone F3 (b) cells were transfected with
either specific PDGFR shRNAs (sh PDGFR) or scrambled shRNAs (sh control).
Transfected cells were selected with 5 μg/ml of Puromycin. Selected cells
were treated with the indicated doses of Imatinib for 48 h. Cell viability was
evaluated by Crystal Violet assay (left panel). Silencing of PDGFR
expression was corroborated by Western blot (right panel). Data represent
the mean ± SEM of three independent experiments seeded in triplicate.
* P < 0.05 versus sh control (EPS 4216 kb)
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